Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases

Head and Neck

Volumn 35, Issue 8, 2013, Pages 1066-1077

  Turri Zanoni, Mario ^a   Medicina, Daniela ^a   Lombardi, Davide ^a   Ungari, Marco ^a   Balzarini, Piera ^a   Rossini, Cristina ^a   Pellegrini, Wilma ^a   Battaglia, Paolo ^b   Capella, Carlo ^b   Castelnuovo, Paolo ^b   Palmedo, Gabriele ^c   Facchetti, Fabio ^a   Kutzner, Heinz ^c   Nicolai, Piero ^a   Vermi, William ^a,d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c Dermatopathologische Gemeinschaftspraxis   (Germany)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

KIT; NRAS; PI3K Akt pathway; RAS MAPK pathway; sinonasal melanoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MYB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CRANIECTOMY; DISTANT METASTASIS; ENDOSCOPIC SURGERY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MELANOMA CELL; MUTATIONAL ANALYSIS; ONCOGENE N RAS; PARANASAL SINUS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINONASAL MUCOSAL MELANOMA; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

KIT; NRAS; PI3K/AKT PATHWAY; RAS-MAPK PATHWAY; SINONASAL MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CYCLIN D1; DNA-BINDING PROTEINS; FEMALE; GENES, MYB; GENES, P16; GENES, RAS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NASAL MUCOSA; PARANASAL SINUS NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PTEN PHOSPHOHYDROLASE; TRANSCRIPTION FACTORS;

EID: 84880702947     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23079     Document Type: Article

References (69)

1. Miller AJ, Mihm MC Jr,. Melanoma. N Engl J Med 2006; 355: 51-65.
2. Dahl C, Guldberg P,. The genome and epigenome of malignant melanoma. APMIS 2007; 115: 1161-1176.
3. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
4. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
5. Lee JH, Choi JW, Kim YS,. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164: 776-784.
6. Wu H, Goel V, Haluska FG,. PTEN signaling pathways in melanoma. Oncogene 2003; 22: 3113-3122.
7. Curtin JA, Busam K, Pinkel D, Bastian BC,. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346.
8. Bastian BC,. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 2003; 22: 3081-3086.
9. Smalley KS, Contractor R, Nguyen TK, et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 2008; 68: 5743-5752.
10. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, Shrager J,. A melanoma molecular disease model. PLoS One 2011; 6: e18257.
11. Dauer EH, Lewis JE, Rohlinger AL, Weaver AL, Olsen KD,. Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg 2008; 138: 347-352.
12. Roth TN, Gengler C, Huber GF, Holzmann D,. Outcome of sinonasal melanoma: clinical experience and review of the literature. Head Neck 2010; 32: 1385-1392.
13. Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer 2010; 116: 2215-2223.
14. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009; 33: 1146-1156.
15. Jethanamest D, Vila PM, Sikora AG, Morris LG,. Predictors of Survival in Mucosal Melanoma of the Head and Neck. Ann Surg Oncol 2011; 18: 2748-2756.
16. Moreno MA, Hanna EY,. Management of mucosal melanomas of the head and neck: did we make any progress? Curr Opin Otolaryngol Head Neck Surg 2010; 18: 101-106.
17. Gerami P, Mafee M, Lurtsbarapa T, Guitart J, Haghighat Z, Newman M,. Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes. Arch Dermatol 2010; 146: 273-278.
18. Smalley KS,. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 2010; 130: 28-37.
19. Franchi A, Alos L, Gale N, et al. Expression of p16 in sinonasal malignant melanoma. Virchows Arch 2006; 449: 667-672.
20. Hussein MR,. Extracutaneous malignant melanomas. Cancer Invest 2008; 26: 516-534.
21. Patrick RJ, Fenske NA, Messina JL,. Primary mucosal melanoma. J Am Acad Dermatol 2007; 56: 828-834.
22. Lund VJ, Howard DJ, Harding L, Wei WI,. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope 1999; 109 (2 Pt 1): 208-211.
23. Krengli M, Masini L, Kaanders JH, et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006; 65: 751-759.
24. Krengli M, Jereczek-Fossa BA, Kaanders JH, Masini L, Beldì D, Orecchia R,. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit Rev Oncol Hematol 2008; 65: 121-128.
25. Benlyazid A, Thariat J, Temam S, et al. Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. Arch Otolaryngol Head Neck Surg 2010; 136: 1219-1225.
26. Yanagi T, Mizoe JE, Hasegawa A, et al. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2009; 74: 15-20.
27. Zenda S, Kawashima M, Nishio T, et al. Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study. Int J Radiat Oncol Biol Phys 2011; 81: 135-139.
28. Smalley KS, Sondak VK, Weber JS,. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009; 24: 643-650.
29. Ashida A, Takata M, Murata H, Kido K, Saida T,. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009; 124: 862-868.
30. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95: 1878-1890.
31. Wong CW, Fan YS, Chan TL, et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 2005; 58: 640-644.
32. Edwards RH, Ward MR, Wu H, et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 2004; 41: 270-272.
33. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-599.
34. Smalley KS, Xiao M, Villanueva J, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009; 28: 85-94.
35. Sekine S, Nakanishi Y, Ogawa R, Kouda S, Kanai Y,. Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites. Virchows Arch 2009; 454: 513-517.
36. Diaz-Flores E, Shannon K,. Targeting oncogenic Ras. Genes Dev 2007; 21: 1989-1992.
37. Downward J,. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
38. Jaiswal BS, Janakiraman V, Kljavin NM, et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 2009; 4: e5717.
39. Rivera RS, Nagatsuka H, Gunduz M, et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008; 452: 27-32.
40. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121: 257-264.
41. Satzger I, Schaefer T, Kuettler U, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 2008; 99: 2065-2069.
42. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14: 6821-6828.
43. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010; 102: 1219-1223.
44. Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011; 17: 1684-1691.
45. Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009; 22: 1446-1456.
46. Carvajal RD, Chapman PB, Wolchok JD, et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009; 27 (suppl):Abstract 9001.
47. Lutzky J, Bauer J, Bastian BC,. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008; 21: 492-493.
48. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26: 2046-2051.
49. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P,. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008; 5: 737-740.
50. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009; 8: 2079-2085.
51. Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011; 117: 2202-2208.
52. Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R,. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy-case report and review of the literature. Dermatology 2010; 220: 77-81.
53. Zhu Y, Si L, Kong Y, et al. Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 2009; 27 (suppl): Abstract e20017.
54. Tate G, Tajiri T, Suzuki T, Mitsuya T,. Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary. Cancer Genet Cytogenet 2009; 190: 15-20.
55. Daniotti M, Ferrari A, Frigerio S, et al. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol 2009; 129: 1759-1768.
56. Lasota J, Miettinen M,. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53: 245-266.
57. Maurel J, Martins AS, Poveda A, et al. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer 2010; 116: 3692-3701.
58. Sakuma Y, Sakurai S, Oguni S, Satoh M, Hironaka M, Saito K,. c-kit gene mutations in intracranial germinomas. Cancer Sci 2004; 95: 716-720.
59. Zheng S, Chen LR, Wang HJ, Chen SZ,. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor. Hepatogastroenterology 2007; 54: 2285-2290.
60. Miettinen M, Lasota J,. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
61. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
62. Alexis JB, Martinez AE, Lutzky J,. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res 2005; 15: 283-285.
63. Gerami P, Pouryazdanparast P, Vemula S, Bastian BC,. Molecular analysis of a case of nevus of ota showing progressive evolution to melanoma with intermediate stages resembling cellular blue nevus. Am J Dermatopathol 2010; 32: 301-305.
64. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002; 62: 3200-3206.
65. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB,. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
66. Stephens L, Williams R, Hawkins P,. Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 2005; 5: 357-365.
67. Aziz SA, Jilaveanu LB, Zito C, et al. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 2010; 16: 6029-6039.
68. Friedlander P, Hodi FS,. Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol 2010; 8: 619-627.
69. Smalley KS, Nathanson KL, Flaherty KT,. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009; 69: 3241-3244.